Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGS1 | P23219 | 1/20 | 0.35 |
| ▸ | GRIK1 | P39086 | 2/20 | 0.35 |
| ▸ | GRIA2 | P42262 | 2/20 | 0.35 |
| ▸ | GRIA4 | P48058 | 2/20 | 0.35 |
| ▸ | GRIK3 | Q13003 | 2/20 | 0.35 |
| ▸ | GRIK5 | Q16478 | 2/20 | 0.35 |
| ▸ | GRIA1 | P42261 | 1/20 | 0.35 |
| ▸ | GRIK2 | Q13002 | 1/20 | 0.35 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.32 |
| ▸ | AKR1C3 | P42330 | 1/20 | 0.31 |
| ▸ | MAPT | P10636 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17512192 | 1.00 | PTGS1 (0.35) | PTGS1GRIK1GRIA2GRIA4GRIK3 | |
| SCHEMBL17512181 | 0.96 | GRIK1 (0.33) | PTGS1GRIK1GRIA2GRIA4GRIK3 | |
| SCHEMBL17512182 | 0.96 | GRIK1 (0.33) | PTGS1GRIK1GRIA2GRIA4GRIK3 | |
| SCHEMBL21714 | 0.79 | — | — | |
| SCHEMBL21716 | 0.79 | — | — | |
| SCHEMBL6573659 | 0.79 | — | — | |
| Acetic Acid SCHEMBL10488048 | 0.77 | FFAR3 (0.39) | PTGS1GRIK1GRIA2GRIA4GRIK3 | |
| SCHEMBL19361064 | 0.74 | PTGS1 (0.41) | PTGS1CYP2C9AKR1C3MAPT | |
| SCHEMBL853609 | 0.74 | PTGS1 (0.41) | PTGS1CYP2C9AKR1C3MAPT | |
| SCHEMBL9626961 | 0.73 | CA2 (0.36) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9718797-B2 | Eight diasteromers of vittatalactone and methods of making, and methods of attracting acalymma vittatum | The United States of America, as represented by the Secretary of Agirculture (US) | 2017-08-01 | — | — | US | claimed |
| US-20160052901-A1 | Eight Diasteromers of Vittatalactone and Methods of Making, and Methods of Attracting Acalymma vittatum | CHEMVEDA LIFE SCIENCES, INC. | 2016-02-25 | — | — | US | claimed |
| US-9718797-B2 | Eight diasteromers of vittatalactone and methods of making, and methods of attracting acalymma vittatum | The United States of America, as represented by the Secretary of Agirculture (US) | 2017-08-01 | — | — | US | disclosed |
| US-20160052901-A1 | Eight Diasteromers of Vittatalactone and Methods of Making, and Methods of Attracting Acalymma vittatum | CHEMVEDA LIFE SCIENCES, INC. | 2016-02-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160052901-A1 | Eight Diasteromers of Vittatalactone and Methods of Making, and Methods of Attracting Acalymma vittatum | DAGLA, NOTUM, DAGLB | PTGS1 3930/4885GRIK1 2215/4885GRIA2 2330/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.